MQR MultiQure S.A.
MultiQure S.A., a biopharmaceutical company, researches and develops biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFß1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the aVß8 integrin. The company was formerly known as Pure Biologics S.A. and changed its name to MultiQure S.A. in August 2026. The company was founded in 2013 and is based in Wroclaw, Poland.…
Industry Peers
BiotechnologyKey Statistics
About MultiQure (WSE: MQR)
›
MultiQure (WSE: MQR) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 4 employees.
The shares were at 1.360 PLN on 19 November 2026, down 78.2% over 52 weeks. Its 52-week range is 1.312 PLN to 7.100 PLN: the price is 80.8% below the high and 3.7% above the low.
Its market capitalisation is 307.02M PLN.
MultiQure reports return on equity of 69.4% and an operating margin of 360.2%.
Its Piotroski F-score is 4 out of 9, an average reading of its financial health.